Diagnosis and Management of Pulmonary Hypertension: The State of the Science
- CME / AMA PRA Category 1 Credit™
- MOC / ABIM MOC Part 2 Credit
Pulmonary hypertension (PH) comprises a group of disorders that reflect an increase in pulmonary arterial pressure. The World Health Organization (WHO) has identified 5 etiologies/types of PH, based on the underlying pathological mechanisms. Initial symptoms of PH are shortness of breath (which often comes on precipitously) and exertional dyspnea. Left untreated, PH ultimately leads to right-heart failure.
A number of therapeutic specialists (cardiology, pulmonology, and primary care, especially internal medicine) are involved in the diagnosis and care of PH. Because symptoms are nonspecific, most patients with PH are not correctly diagnosed for 2 to 5 years after symptom onset, and life expectancy is only approximately 3-5 years after diagnosis. Diagnosis and Management of Pulmonary Hypertension: The State of the Science is designed to help improve the diagnosis of PH by exploring its complex nature and poor prognosis. The education will help clinicians recognize suspected PH and refer those patients to a PH specialty center, where interdisciplinary teams are available and newer treatments can be offered to prolong life and improve QoL.
Welcome and Introduction
Pathobiology of Pulmonary Hypertension
Specific Advanced Drug Therapies
The intended audiences for this educational initiative include community-based cardiologists, internal medicine specialists, and other healthcare providers who manage PH patients.
This program is designed to address the following NAM competencies: provide patient-centered care and employ evidence-based practice.
At the conclusion of this activity, participants should be able to demonstrate the ability to:
- Conduct prompt diagnostic evaluation of patients suspected of having PH, and arrange for prompt diagnosis
- Describe the clinical properties of specific advanced drug therapies, and explain the rationale for early treatment initiation by specialty centers to achieve the best clinical outcomes
The Potomac Center for Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Potomac Center for Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
ABIM MOC DESIGNATION STATEMENT
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
To receive CME credit and/or MOC points, you MUST pass the post-test and complete the evaluation. For ABIM MOC points, your information will be shared with the ABIM through PCME’s ACCME Program and Activity Reporting System (PARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.
For questions regarding CME credit or the evaluation, please email firstname.lastname@example.org.
Assistant Professor of Medicine
Harvard Medical School
Associate Physician, Division of Cardiovascular Medicine, Brigham and Women’s Hospital
Co-Director, Pulmonary Vascular Disease Center
Boston VA Healthcare System
Dr. Maron has co-authored numerous scientific manuscripts and is the lead editor of a recently published textbook on pulmonary vascular disease. His work is funded by the National Institutes of Health, American Heart Association, Cardiovascular Medical Research and Education Foundation, Scleroderma Foundation, and the Klarman Family Foundation. He is also the recipient of the distinguished Eleanor and Miles Shore Scholar in Medicine, American Society of Clinical Investigator Young Physician-Scientist Award, and the Harvard Medical School Excellence in Teaching award.
Director, Dyspnea & Pulmonary Hypertension Centers
Director, Cardiovascular Medicine Unit
University of Utah
Salt Lake City, UT
Program Faculty Disclosures
Bradley A. Maron, MD – Nothing to disclose
John J. Ryan, MD, MRCPI, FACC, FAHA – Advisory Board: Bayer
Non-faculty Content Contributors Disclosures
Terry Ann Glauser, MD, MPH; Blair St. Amand; Lindsay Scott, PT, DPT, ATC; Ashley Marostica, RN, MSN, CCM – Nothing to disclose
INSTRUCTIONS FOR PARTICIPANTS AND OBTAINING CME CREDIT
INSTRUCTIONS FOR OBTAINING MOC Points
ABIM six-digit ID number
First and last name
Date of birth (mm/dd)
Provided by Potomac Center for Medical Education
This activity is supported by an educational grant from Actelion Pharmaceuticals US, Inc. and Bayer US.
Improving Outcomes for Patients with Severe Hypercholesterolemia
Credits 1.00 (60 min)
FIGHTING THE UPHILL BATTLE: Current Evidence in Obesity Management
Credits 1.00 (60 min)